vasculostatin-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-vasculostatin(Cat#: CyOV-0008XY)

This product is a vasculostatin expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP27 deleted. ICP27 is highly cytotoxic probably due to its secondary role of preventing the splicing of pre-mRNAs in favour of translation from the mainly unspliced hepes RNAs. Deletion of ICP27 might produce a safer and less cytotoxic system when combined with other oncolytic-rendered modifications. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.

Specifications

Family Herpesviridae
Species Herpes simplex virus
Serotype Herpes simplex virus 1
Backbone HSV-1 (ΔICP27)
Backbone Background Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification ΔICP27
Promoter CMV
Transgene vasculostatin
Type of Transgene Cytokine
Related Target/Protein Vasculostatin
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Tumor

Transgene

Alternative Names vasculostatin

Information

Introduction Vasculostatin, a proteolytic fragment of brain Angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor, inhibited migration of endothelial cells in vitro and dramatically reduced in vivo angiogenesis.

Customer Reviews and Q&As

There are currently no customer reviews or questions for vasculostatin-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-vasculostatin (CyOV-0008XY). Click the button below to contact us or submit your feedback about this product.

All products and services are for Research Use Only. Not For Clinical Use.

Other products

PRODUCTS

Online Inquiry